Given that inhibition of myostatin is a potent inducer of muscular hypertrophy and thus has been considered as a potential therapeutic approach for dystrophin deficiency-related muscular dystrophies in humans, manipulating mice to model the cat phenotype, in particular to evaluate the role of myostatin inhibition and other inducers of muscular hypertrophy in the context of dystrophin deficiency, could potentially be informative in terms of identifying better therapeutic approaches. Here, MSTN is linked to neuromuscular disease caused by qualitative or quantitative defects of dystrophin.